INVIVYD INC. - COMMON STOCK

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

10 Jan 2025 06:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 06:05:00 By Nasdaq GlobeNewswire

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

14 Nov 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

12 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

06 Nov 2024 07:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

06 Nov 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

29 Oct 2024 06:03:00 By Nasdaq GlobeNewswire

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

29 Oct 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

16 Oct 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

01 Oct 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

23 Sep 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

12 Sep 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate in Upcoming Investor Conferences

05 Sep 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

04 Sep 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

03 Sep 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

27 Aug 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 Aug 2024 07:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

12 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

01 Jul 2024 06:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

14 Jun 2024 06:01:00 By Nasdaq GlobeNewswire